Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

By leading Pact Pharma Inc.’s $75 million series C round, the ex-Kite partners at Vida Ventures finally have a chance to advance neoantigen-specific T cells for solid tumors, an area of keen interest they weren’t

Read the full 354 word article

User Sign In